Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025800 | 0.87 | IRAK4 (0.62) | IRAK4CRBNLRRK2IKZF2IKZF1 | |
| SCHEMBL21026009 | 0.87 | IRAK4 (0.62) | IRAK4CRBNLRRK2IKZF2IKZF1 | |
| SCHEMBL23705491 | 0.82 | CRBN (0.59) | IRAK4CRBNHRH3DDB1 | |
| SCHEMBL30058706 | 0.82 | CRBN (0.59) | IRAK4CRBNHRH3DDB1 | |
| SCHEMBL22291300 | 0.77 | CRBN (0.58) | IRAK4CRBNLRRK2IKZF2IKZF1 | |
| SCHEMBL23705600 | 0.77 | CRBN (0.56) | IRAK4CRBNLRRK2DDB1 | |
| SCHEMBL26036741 | 0.77 | CRBN (0.47) | IRAK4CRBNDDB1 | |
| SCHEMBL26037371 | 0.77 | CRBN (0.47) | CRBNDDB1 | |
| SCHEMBL29334462 | 0.77 | CRBN (0.46) | CRBNDDB1MAOA | |
| SCHEMBL20128894 | 0.77 | MAOA (0.57) | IRAK4CRBNLRRK2DDB1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885CRBN 5/4885LRRK2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.